Google
Trusted Resources: News & Events
Latest announcements and gatherings
In Support of Rare Disease Patients Impacted by COVID-19, NORD Launches Premium and Limited Medical Relief Program
United with more than 25 million Americans living with rare diseases, the National Organization for Rare Disorders (NORD®) today launched its COVID-19 Premium & Medical Relief Program to provide vital support to members of the rare disease community affected by the COVID-19 pandemic. The program will assist those with a confirmed rare disease diagnosis who have been directly impacted by the pandemic through a job loss, reduced work hours, furlough, quarantine, etc.
“COVID-19 poses significant threats to the rare disease community, given the susceptibility of those with chronic conditions and the economic challenges that affect their ability to weather this storm. We are hearing from patients who have been furloughed or laid off and desperately need financial support for insurance, COBRA payments, co-pays and medical expenses,” said Pamela Gavin, Chief Strategy Officer for NORD. “Through this new program, we are providing premium and limited medical assistance to rare patients who need it most during this crisis.”
+myBinderRelated Content
-
National Briefing with CDC: COVID-19 and the Chronic Disease CommunityApril 29th, 2020 from 2PM – 3PM EDT A...
-
How to Talk to Your Kids About CoronavirusEarlier this week, I overheard my kids e...
-
Supermarkets Offer Special Hours for Older ShoppersSome grocery store chains across the U.S...
-
RDLA April 2020 Legislative Webinar – Rare Disease Legislative AdvocatesRare Disease Legislative Advocates Powe...
-
Coronavirus (COVID-19) – General Information | Centers for Disease Control and PreventionSteps to Help Prevent the Spread of COVI...
-
COVID-19 Outcomes Among Individuals With Sickle Cell Disease by IASCNAPA – WebinarLearning Objectives: • Understand how...
-
New York State Sickle Cell Advocacy Network (NYSSCAN)New York State Sickle Cell Advocacy Netw...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.